Showing 3581-3590 of 7247 results for "".
- Hair Prosthetic Injuries Disproportionately Affect Women in US Emergency Departmentshttps://practicaldermatology.com/news/hair-prosthetic-injuries-disproportionately-affect-women-in-us-emergency-departments/2485826/A recent analysis of the National Electronic Injury Surveillance System (NEISS) looking at hair prosthetic–related injuries presenting to US emergency departments (EDs) between 2013 and 2022 suggested these injuries disproportionately affect women.
- Analysis: Biologics Linked to Lower Cardiometabolic Risk in HShttps://practicaldermatology.com/news/analysis-biologics-linked-to-lower-cardiometabolic-risk-in-hs/2485805/Biologics were associated with a lower incidence of type 2 diabetes mellitus (T2DM) and cardiovascular events vs. no biologic use in a TriNetX cohort of 291,283 patients with hidradenitis suppurativa (HS), according to a new study in the Journal of Drugs in Dermatology. Investigat
- Study: HS Linked to Hyperglycemia and Altered Amino Acid Metabolism in Plasmahttps://practicaldermatology.com/news/study-hs-linked-to-hyperglycemia-and-altered-amino-acid-metabolism-in-plasma/2485657/New research in the Archives of Dermatological Research shows consistent metabolic alterations in patients with moderate-to-severe hidradenitis suppurativa (HS, particiularly regarding energy and amino acid metabolism, that
- Prolactin Receptor Blockade May Promote Hair Growth via Follicular Stem Cell Activationhttps://practicaldermatology.com/news/prolactin-receptor-blockade-may-promote-hair-growth-via-follicular-stem-cell-activation/2485612/Blocking prolactin receptor (PRLR) signaling with the investigational antibody ABS-201 promoted hair follicle growth and stem cell activation in human male scalp skin models, according to preclinical data from Jérémy Chéret, PhD, MSc, at the South Beach Symposium
- Delgocitinib Improves Patient-Reported Outcomes Across Chronic Hand Eczema Subtypeshttps://practicaldermatology.com/news/delgocitinib-improves-patient-reported-outcomes-across-chronic-hand-eczema-subtypes/2485611/Patient-reported outcome (PRO) data from the phase 3 DELTA 1 and DELTA 2 trials suggest that topical delgocitinib cream provides clinically meaningful symptom relief across major subtypes of chronic hand eczema (CHE), according to a poster from Robert Bissonnette,
- Nutrafol Launches Men 50+ Formula Targeting Age-Related Hair Thinninghttps://practicaldermatology.com/news/nutrafol-launches-men-50-formula-targeting-age-related-hair-thinning/2485568/Nutrafol announced an expansion of its men’s portfolio with the launch of Nutrafol Men 50+, a product designed specifically for men aged 50 years and older with thinning hair. According to the company, men entering their 50s ex
- Imagining a Better Future for Hidradenitis Suppurativahttps://practicaldermatology.com/news/imagining-a-better-future-for-hidradenitis-suppurativa/2485556/Hidradenitis suppurativa (HS) has long been misunderstood, underdiagnosed, and undertreated. However, at a recent panel discussion led by Vivian Shi, MD, at
- Empowering the HS Community Through Wellness, Nutrition, and Compassionhttps://practicaldermatology.com/news/empowering-the-hs-community-through-wellness-nutrition-and-compassion/2485555/Wellness goes beyond skin when it comes to managing hidradenitis suppurativa (HS). In an effort to spread awareness of that concept, HS Connect founder and CEO Brindley Brooks and COO Cristina Curp took the stage at
- Deuruxolitinib Produces Progressive Hair Regrowth in Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-produces-progressive-hair-regrowth-in-severe-alopecia-areata/2485553/Deuruxolitinib produced progressive and clinically meaningful scalp hair regrowth in patients with severe alopecia areata, according to “Deuruxolitinib Improves Scalp Hair Regrowth Over Time in Patients With Severe Alopecia Areata,” a poster by Natasha A. Mesinkovska, MD, PhD, et al presented as
- Povorcitinib Improves Lesion Burden and Pain in Hidradenitis Suppurativahttps://practicaldermatology.com/news/povorcitinib-improves-lesion-burden-and-pain-in-hidradenitis-suppurativa/2485551/Oral povorcitinib produced early and sustained improvements in lesion burden and pain in patients with moderate-to-severe hidradenitis suppurativa (HS), according to “Effect of Povorcitinib on Hidradenitis Suppurativa Lesions Through 24 Weeks in STOP-HS Trials,” a poster by Jennifer L. Hsiao, MD,